Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207776 | 0.83 | AHR (0.42) | AHRKDM4EGPR84DAOHTR2A | |
| SCHEMBL207535 | 0.74 | AHR (0.42) | AHRGPR84HTR2ATRPM8 | |
| SCHEMBL1965665 | 0.73 | GPR84 (0.37) | GPR84 | |
| SCHEMBL21052832 | 0.72 | DAO (0.47) | AHRKDM4EGPR84DAOHTR2A | |
| SCHEMBL6357105 | 0.69 | ALDH1A1 (0.37) | KDM4E | |
| SCHEMBL1968319 | 0.69 | MEN1 (0.47) | KDM4EGPR84HTR2A | |
| SCHEMBL17423817 | 0.69 | — | — | |
| SCHEMBL5365900 | 0.69 | TAAR1 (0.49) | KDM4E | |
| SCHEMBL21052825 | 0.68 | KDM4E (0.45) | KDM4EGPR84DAOHTR2AMPO | |
| SCHEMBL4502393 | 0.68 | KDM4E (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512867-B1 | NOVEL COMPOUNDS | DSM IP ASSETS BV (NL) | 2020-12-16 | — | — | EP | claimed |
| CN-111533767-A | Tetradentate phosphine ligand and preparation method thereof, hydroformylation catalyst and reaction method, and preparation method of 1, 3-propylene glycol | 卢海元 | 2020-08-14 | — | — | CN | claimed |
| CN-107406423-B | Potent gamma-secretase modulators | 通用医疗公司 | 2020-06-16 | — | — | CN | claimed |
| EP-3356345-A1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-08 | — | — | EP | claimed |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | claimed |
| EP-3212633-A1 | POTENT GAMMA-SECRETASE MODULATORS | The General Hospital Corporation (US) | 2017-09-06 | — | — | EP | claimed |
| WO-2016070107-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-06 | — | — | WO | claimed |
| WO-2016003296-A1 | (QUINOLINE OR ISOQUINOLINE)SULFONAMIDES OF CYCLIC AMINES AS ANTIPSYCHOTIC DRUGS | INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK (PL) | 2016-01-07 | — | — | WO | claimed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | claimed |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | US | claimed |
| US-6333339-B1 | CENTRAL SYSTEM DISORDERS, SCHIZOPHRENIA AND COGNITION ACTIVATORS | MERCK PATENT GELLSCHAFT MIT BESCHRANKTER (DE) | 2001-12-25 | — | — | US | claimed |
| CN-1325384-A | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2001-12-05 | — | — | CN | claimed |
| EP-1129074-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | claimed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | claimed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | claimed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | claimed |
| WO-2000027819-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | claimed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | claimed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, PLIN1 | AHR 1744/4885KDM4E 2820/4885GPR84 1027/4885 |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, APP | AHR 3351/4885KDM4E 3581/4885GPR84 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.